Navigation Links
MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
Date:1/30/2008

ization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front- loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(TM). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more on MiddleBrook, please visit http://www.middlebrookpharma.com.

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on MiddleBrook's current expectations and assumptions. These statements are not guarantees of future performance and are subject to a number of risks and uncertainties that would cause actual results to differ materially from those anticipated. The words, "believe," "expect," "intend," "anticipate," and variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward- looking. Statements in this announcement that are forward-looking include, but are not limited to, statements about the Company's future development plans, clinical trials, potential commercial success, and any financial forecasts included in this announcement.

The actual results realized by MiddleBrook could differ materially from these forward-looking statements, depending in particular upon the risks and uncertainties described in the Company's fil
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Access Pharmaceuticals Announces $2.7 Million New Equity
3. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
4. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
5. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
6. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
7. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
8. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
9. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
10. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
11. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... CALGARY , June 30, 2015 /PRNewswire/ - ... ("Shareholders") of common shares of Resverlogix have approved ... to Eastern Capital Limited of 5,600,000 units at ... Private Placement"), each unit being comprised of one ... for aggregate proceeds of approximately CAD$15 million; and ...
(Date:6/30/2015)... 30, 2015  Today, Americord Registry, one of the fastest ... Horne , a partner at Kirkland & Ellis LLP, as ... Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   "We are thrilled ... says Martin Smithmyer , CEO of Americord. "He brings ... that will assist Americord,s growth and vision." ...
(Date:6/30/2015)... ... ... The maximum number of shares proposed to be purchased in the tender ... restricted stock). On June 29, 2015, the last trading day prior to the commencement ... OTCBB was $2.29 per share. , The tender offer will expire on July 28, ...
(Date:6/30/2015)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... on the development of autologous cell therapies, announced today ... clinical trial of RCT-01, being tested for the ... enrolled and their tissue biopsy sent for processing ... of non-bulbar dermal sheath (NBDS) cells isolated from ...
Breaking Biology Technology:Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Americord Registry Announces Andrew Horne as Advisory Board Member 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4
... Roles as Vice Chairman of The Foundry and Advisor to ForSight ... ... Labs, MENLO PARK, Calif., Sept. 4 Morgenthaler Ventures, (http://www.morgenthaler.com/ventures ... technology investments, today announced the,addition of Hank Plain as partner in ...
... PRINCETON, N.J., Sept. 4 Medarex, Inc.,(Nasdaq: MEDX ... at the Bear,Stearns 20th Annual Healthcare Conference at 9:00 ... is being held at The Grand Hyatt,New York in ... and,will be available for replay through the Webcast page ...
... Paves the Way for the Phase III Clinical ... Commercialization of THR-100 in Developing ... NV (Euronext,Brussels: THR), a biotechnology company focused on ... technology transfer to Bharat,Biotech International Limited (Hyderabad, India) ...
Cached Biology Technology:Hank Plain Joins Morgenthaler Ventures as Partner 2Hank Plain Joins Morgenthaler Ventures as Partner 3Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference 2ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 2ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 3ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 4
(Date:6/24/2015)... Biometry authentication provider KeyLemon today announced ... one face in. Logo - ... in, entering the expanding biometric authentication market in ... answer to the password problem. With advanced face ... KeyLemon, one face in allows users to securely ...
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, ... and authentication solutions, today announced enhanced functionality of ... authentication solution.  The enhancements build on the ... the DigitalPersona Altus platform and provide expanded ... In today,s environment of increasing ...
(Date:6/17/2015)... , and HILDEN, Germany , June ... QGEN ; Frankfurt Prime Standard: QIA) today launched new Investigator ... in forensic laboratories in the United States ... to simultaneously analyze multiple key genomic markers (short tandem repeats ... Quality Sensor to evaluate the quality of DNA in ...
Breaking Biology News(10 mins):KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5
... CITY While researching new ways to stop the ... Health Sciences Center, have discovered a compound that has ... appears in the journal Gene Regulation and Systems Biology. ... clinical trials, successfully stopped normal cells from turning into ...
... gel electrophoresis" Most teenagers wouldnt have a clue what ... Trigiano knows the protocol inside and out. When Andrew ... the University of Tennessee, was looking for an interesting ... differences in popular brands of Easter egg dyes, Trigianos ...
... will help archeologist Bill Middleton peer into the ancient ... hyperspectral data will help build the most accurate and ... state of Oaxaca, where the Zapotec people formed the ... you ask someone off the street about Mexican archeology, ...
Cached Biology News:Chemical compound prevents cancer in lab 2DNA fingerprinting simplified 2Archaeologist uses satellite imagery to explore ancient Mexico 2Archaeologist uses satellite imagery to explore ancient Mexico 3
Mouse Laminin-1 MAb (Clone AL-3)...
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
IEX-1 S/L (H-20)...
WIF-1 (N-20)...
Biology Products: